NAS-181

NAS-181
Clinical data
Other namesNAS181; MCOMM
Drug classSerotonin 5-HT1B receptor antagonist
Identifiers
  • (2R)-2-[[3-(morpholin-4-ylmethyl)-2H-chromen-8-yl]oxymethyl]morpholine
CAS Number
PubChem CID
UNII
ChEMBL
Chemical and physical data
FormulaC19H26N2O4
Molar mass346.427 g·mol−1
3D model (JSmol)
  • C1CO[C@H](CN1)COC2=CC=CC3=C2OCC(=C3)CN4CCOCC4
  • InChI=1S/C19H26N2O4/c1-2-16-10-15(12-21-5-8-22-9-6-21)13-25-19(16)18(3-1)24-14-17-11-20-4-7-23-17/h1-3,10,17,20H,4-9,11-14H2/t17-/m1/s1
  • Key:RTKDBEOSPDFLGD-QGZVFWFLSA-N

NAS-181, also known as MCOMM, is a selective rodent serotonin 5-HT1B receptor antagonist which is used in scientific research.

In animals, NAS-181 has been found to strongly increase acetylcholine levels in the frontal cortex and hippocampus. It has been found to block memory impairment induced by the antimuscarinic agent scopolamine and by the NMDA receptor antagonist dizocilpine (MK-801). Injection of NAS-181 directly into the nucleus accumbens has also been found to reverse the prosocial behavior induced by the serotonin releasing agent MDMA in animals.

NAS-181 was first described in the scientific literature by 1998. The drug was discovered by researchers at Astra Arcus.

See also